CIK 0001745999 · Large accelerated filer
Beam Therapeutics Inc.
Sign in to watch- Ticker
- BEAM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-327-8775
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Former names
- Beam Therapeutics Inc.
- 4 Grant or award Chief Financial Officer acquired 27,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 27,500 shares (grant or award)
- 4 Grant or award President acquired 35,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 27,500 shares (grant or award)
- 4 Planned sale CEO sold 60,000 shares at $33.86 ($2,031,402)
- 4 Open-market sale See Remark 1 sold 901,565 shares at an average $30.55 ($27,545,051)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale CEO sold 60,000 shares at $25.33 ($1,519,800)
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 1,907 shares at $26.42 ($50,383)
- 4 Other disposition 10% owner disposed of 29,549 shares (other)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Legal Officer sold 10,000 shares at an average $30.50 ($305,000)
- 4 Planned sale Chief Medical Officer sold 3,448 shares at $18.70 ($64,478)
- 4 Option exercise President and CSO acquired 90,900 shares (option exercise)
- 4 Planned sale Chief Legal Officer sold 388 shares at $22.85 ($8,866)
- 4 Planned sale Chief Medical Officer sold 391 shares at $30.48 ($11,918)
Page 6 of 12 · 238 filings